TGFβ-tumor protector effects have been explained through a reduction in c-Myc levels [63] and the concomitant stimulation of some cyclin-dependent kinase inhibitors (mainly p15INK4B and p21CIP1 involved in cell cycle [64]). Here, MYC is linked to neoplasm.